

## ***Salmonella* and cancer: from pathogens to therapeutics\***

Paulina Chorobik, Dominik Czaplicki, Karolina Ossysek and Joanna Bereta<sup>✉</sup>

Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Kraków, Kraków, Poland

**Bacterial cancer therapy is a concept more than 100 years old — yet, all things considered, it is still in early development. While the use of many passive therapeutics is hindered by the complexity of tumor biology, bacteria offer unique features that can overcome these limitations. Microbial metabolism, motility and sensitivity can lead to site-specific treatment, highly focused on the tumor and safe to other tissues. Activation of tumor-specific immunity is another important mechanism of such therapies. Several bacterial strains have been evaluated as cancer therapeutics so far, *Salmonella* Typhimurium being one of the most promising. *S. Typhimurium* and its derivatives have been used both as direct tumoricidal agents and as cancer vaccine vectors. VNP20009, an attenuated mutant of *S. Typhimurium*, shows significant native toxicity against murine tumors and was studied in a first-in-man phase I clinical trial for toxicity and anticancer activity. While proved to be safe in cancer patients, insufficient tumor colonization of VNP20009 was identified as a major limitation for further clinical development. Antibody-fragment-based targeting of cancer cells is one of the few approaches proposed to overcome this drawback.**

**Key words:** bacterial cancer therapy, immunotherapy, cancer vaccine, tumor targeting, *Salmonella*, VNP20009

**Received:** 01 May, 2013; **accepted:** 26 June, 2013; **available on-line:** 05 July, 2013

### **INTRODUCTION**

It was at the end of the 19<sup>th</sup> century that bacteria were for the first time intentionally applied for cancer treatment. William Coley, a bone sarcoma surgeon at the Memorial Hospital in New York, having conducted a thorough literature search, found 47 well-documented cases of beneficial influence of serious bacterial infections in tumor patients (McCarthy, 2006). On the basis of the then-available data he concocted a mixture of killed *Streptococcus pyogenes* and *Serratia marcescens* bacteria, which became known as Coley's toxin. Over the next forty years Coley applied his toxin to almost 1000 patients who suffered from various types of inoperable cancers. Striving to improve the effectiveness of the therapy, he used various doses of his toxin, different regimens and durations of treatment, as well as different routes of application and therefore it is difficult to fully comprehend his enormous work. In many cases several-month treatment resulted in complete tumor regression. The five-year survival period for patients suffering from inoperable carcinomas ranged from 34 to 73%, and for those suffering from inoperable sarcomas was in the range between 13 and 79%, varying with the tumor subtype (Green & Hopton Cann, 2007). However, the results of

Coley's treatment have been non-reproducible, uncertain, and unpredictable and therefore his therapy often met with strong criticism from the medical community. At the beginning of the 20<sup>th</sup> century it was gradually displaced by newly developing radiotherapy, which resulted in fast tumor destruction and pain relief, although not necessarily in complete tumor eradication, especially at the stage of advanced, metastatic disease.

With the progress of immunology it became clear that the mechanism of action of Coley's toxin involves activation of the immune system and a multilevel modulation of immune response. This understanding restored interest in possible therapeutic applicability of Coley's approach. Richardson and coworkers (1999) compared the effectiveness of Coley's toxin with contemporary cancer therapies based on published results concerning patients treated with Coley's toxin and matched controls from National Cancer Institute's Surveillance Epidemiology End Result database (Richardson *et al.*, 1999). They found higher rates of ten-year survival of Coley's patients compared to patients subjected to modern treatment in kidney cancer (33 *vs.* 23%), ovarian cancer (55 *vs.* 29%), and sarcoma (50 *vs.* 38%), which gives food for thought. The attempts to re-evaluate Coley's concept are undertaken anew. In 2012 the new phase 1 clinical trial investigating the safety and the dosage of biochemically well-defined and good manufacturing practice (GMP)-compliant Coley's toxin, presently known as MBV (mixed bacterial vaccine) was started in the Ludwig Institute for Cancer Research. It involves patients suffering from cancers expressing NY-ESO-1 antigen, including metastatic melanoma, head and neck carcinoma, sarcoma and prostate cancer (Karbach *et al.*, 2012). The results of the trial have not been published yet.

In line with Coley's concept of using bacteria in cancer therapies, other bacterial species were evaluated

<sup>✉</sup>e-mail: joanna.bereta@uj.edu.pl

\*Presented at 40th Jubilee Winter School of the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University "Contemporary insights into cancer. Risk, perspectives, expectations", February 16–21, 2013, Zakopane, Poland.

Abbreviations: BCG, Bacillus Calmette-Guérin; CEA, CarcinoEmbryonic Antigen; CTL, Cytotoxic T Lymphocyte; DC, Dendritic Cell; GFP, Green Fluorescent Protein; HbCAG, core antigen of hepatitis B virus; IFN $\gamma$ , Interferon gamma; IL-12, Interleukin 12; IL-18, Interleukin 18; LLO, Listeriolysin; mAFP, mouse Alpha-FetoProtein, MHC, Major Histocompatibility Complex, mPSCA, mouse Prostate Stem Cell Antigen, MTD, Maximum Tolerated Dose; PAMP, Pathogen-Associated Molecular Pattern, PBS, Phosphate Buffered Saline; scFv, single chain variable fragment antibody; SCV, Salmonella-Containing Vacuole; shRNA, short hairpin RNA; Smac, Second mitochondria-derived activator of caspases; SPI, Salmonella Pathogenicity Island; STAT3, Signal Transducer and Activator of Transcription 3; T3SS, Type III Secretion System; TAA, Tumor-Associated Antigen, TNF, Tumor Necrosis Factor, TRAIL, TNF-Related Apoptosis-Inducing Ligand, Treg, regulatory T cells, TRP2, Tyrosinase-Related Protein 2, TUNEL, Terminal deoxynucleotidyl transferase dUTP Nick End Labeling, VEGFR, Vascular Endothelial Growth Factor Receptor.

for a possible anti-tumor effect. Early experiments on “hemorrhagic allergy” in 1910s and 1920s showed that animals injected with bacterial filtrates developed hemorrhagic necrosis upon re-challenge with bacteria (so called Sanarelli-Shwartzman phenomenon). In particular, this condition was caused by *Bacillus typhosus*, which used to be a synonym for *Salmonella Typhi* at that time (Shwartzman, 1928). Interestingly, this shock syndrome induced a therapeutic effect in tumor-bearing animals (Shwartzman, 1935). However, the studies were discontinued due to very high treatment-related mortality; nowadays the adverse effects can be explained by strong stimulation of proinflammatory cytokines including tumor necrosis factor (TNF) by endotoxin and other bacterial products. *Bacillus Calmette-Guerin* (BCG), attenuated bovine tuberculosis bacteria (*Mycobacterium bovis*), has been used for decades as a vaccine protecting against tuberculosis. However, it also appeared to be one of the most successful cancer immunotherapeutics. BCG, in the form of repeated intravesical instillations, has already been in use for over 30 years as a standard method to prevent cancer recurrence after endoscopic surgery of intermediate- and high-risk non-muscle invasive bladder cancer (Kawai *et al.*, 2013). It is also effective against inoperable bladder carcinoma *in situ* resulting in a 70–75% complete response rate (Alexandroff *et al.*, 1999). Unfortunately, in other tumor types BCG application has not proved to be more effective than conventional therapies (Alexandroff *et al.*, 1999).

#### BACTERIAL CANCER THERAPIES CAN ADDRESS THE KEY ISSUES IN CANCER TREATMENT

Starting from 1946, chemotherapy gradually became the principal therapeutic strategy in cancer and bacterial therapies were largely forgotten. The success of small-molecule drugs in cancer treatment was remarkable, but turned out to be incomplete. Chemotherapy of many tumors suffers from limited efficacy towards cancer cells and damaging action towards normal cells. Both phenomena have a significant impact on therapeutic outcomes, being responsible for incomplete tumor killing and adverse effects in other tissues. The two factors responsible for those clinical drawbacks are: low specificity towards cancer tissue and insufficient penetration of the tumor by chemotherapeutics. Cancer cells form a complex and heterogeneous system with areas of high metabolism, rich in nutrients and oxygen, as well as distal regions of poor perfusion, quiescence and necrosis (Saunders *et al.*, 2012).

The use of bacteria as anticancer agents might have multiple advantages over other therapeutic approaches. Bacterial therapies can benefit from microbial metabolism, motility and sensitivity to address a number of issues related to currently used treatment modalities. One of the most important issues, relevant to virtually all chemotherapeutic and biological treatments, is limited accessibility of the tumor tissue to passively-distributed therapeutics. Both in the case of small molecule drugs, as well as larger molecules — cytokines, antibodies or even viruses — the therapeutic agent diffuses from the bloodstream into the periphery, with no transport system that could cross biological barriers, act against haemodynamic gradients or facilitate preferential accumulation in the tumor tissue. In fact systemic delivery of passive therapeutics produces relatively large drug concentrations in the bloodstream and relatively low drug concentrations in the tumor, resulting in limited efficacy and

increased extratumoral toxicity. Bacteria offer unique mechanisms that can facilitate site-specific treatment, highly focused on the tumor and safe to other tissues. This can be possible due to several features of bacteria-based therapeutics:

#### Environmental sensing

Tumor tissue has a complex and heterogenic metabolism that makes it particularly resistant to systemic treatment. The natural ability of bacteria to receive signals via chemoreceptors can be used to effectively target this unique microenvironment. Oxygen concentration is one of the most important signals for anaerobic bacteria and is of particular interest in anticancer therapy since hypoxia is a common feature of tumors. Moreover, auxotrophic bacterial strains that rely on the uptake of certain metabolites can recognize the tumor microenvironment as a source of nutrients. This phenomenon can facilitate specific accumulation of bacteria in the tumor. One of the most effective examples is the use of *Clostridium* spores that can only germinate in oxygen-free tumor regions (Dang *et al.*, 2001).

#### Motility

The bacterial microorganism is not only capable of detecting chemoattractants, but can also actively follow chemical gradients. This contrasts with passive therapeutics that simply diffuse into tissues from the circulation. Bacteria are able to penetrate deep into the tumor tissue and perform specific actions, e.g. express proteins or transfer genes, to tumor cells localized remotely from the vasculature. This feature can also allow bacteria to cross physiological barriers and accumulate in cellular regions that are either distant and inaccessible for passive therapeutics or quiescent and unresponsive to chemotherapy. For example, motile strains of *Salmonella* were shown to effectively penetrate tumor tissue *in vitro* (Toley & Forbes, 2012). However, the role of bacterial motility in *in vivo* tumor localization is unclear (Stritzker *et al.*, 2010).

#### Active delivery

Unlike chemical or biological molecules, microorganisms are metabolically active and are able to perform specific metabolic tasks at the tumor site. These include the production of cytotoxic agents (e.g. bacterial toxin), expression of immunomodulatory molecules (e.g. cytokine) or enzymatic conversion of a prodrug into an active therapeutic. Strains derived from intracellular pathogens can infect tumor cells and deliver specific proteins or genes to the tumor tissue (St Jean *et al.*, 2008). Nevertheless, the intratumoral action is not always necessary as bacteria can also express tumor-related antigens to stimulate systemic anticancer immune responses. A *Listeria monocytogenes*-based cancer treatment that has recently entered clinical development is an example of this approach, where the bacterium delivers tumor antigens directly to the antigen presenting cells (Singh & Wallecha, 2011).

#### Controlled propagation

Preferential growth in tumor tissue exhibited by many bacterial species is not exclusive to bacteria; experimental oncolytic viral therapies are based on a similar principle. However, once administered to the patient viral vectors are beyond external control. In contrast, bacterial therapeutics are susceptible to antibiotic treatment and there-

**Table 1. Overview of candidate live attenuated bacteria strains for cancer treatment.**

Parental species/strain	General features	
<i>Mycobacterium bovis</i> (BCG)	Obligate aerobic, non-motile, gram-positive, facultatively intracellular, pathogenic to animals	Approved for bladder cancer management as intravesical BCG therapy, proven to be more effective than intravesical chemotherapy (reviewed by Kawai <i>et al.</i> , 2013).
<i>Salmonella</i> Typhimurium ssp.	Facultative anaerobe, motile, gram-negative, facultatively intracellular, broad-host pathogen	Transplantable and genetic animal tumor models in immunodeficient and immunocompetent mice. Completed and ongoing phase 1 clinical trials in melanoma ( <i>S. Typhimurium</i> VP20009) (Toso <i>et al.</i> , 2002) and liver cancer patients ( <i>S. Typhimurium</i> x4550 expressing IL-2), respectively.
<i>Salmonella</i> Typhi ssp.	Facultative anaerobe, motile, gram-negative, facultatively intracellular, human-adapted pathogen	Growth inhibition of subcutaneous LM3 mammary adenocarcinoma in BALB/c mice after <i>S. Typhi</i> CVD 915 multiple treatment (injection into the tumor, peritumoral tissue and draining lymph node areas) (Vendrell <i>et al.</i> , 2011). Ongoing phase 1 clinical trial with licensed oral <i>S. Typhi</i> Ty21a strain carrying VEGFR2 coding sequence under the control of eukaryotic promoter for anti-angiogenic therapy and immunotherapy of pancreatic cancer (Niethammer <i>et al.</i> , 2012).
<i>Clostridium</i> sp. spores	Anaerobic, gram-positive, sporulating, vegetative forms are motile; pathogenicity: <i>C. sporogenes</i> — rarely, <i>C. novyi</i> — yes, <i>C. beijerinckii</i> — no	Strains modified to deliver pro-drug converting enzymes, cytokines, antibodies against tumor antigens. Spores administered systematically germinate and multiply only in hypoxic/necrotic areas of tumors causing significant oncolysis (reviewed by Umer <i>et al.</i> , 2012) Ongoing phase 1 clinical trial of <i>C. novyi</i> -NT spores in patients with solid tumor malignancies <sup>1</sup> .
<i>Escherichia coli</i> Nissle 1917	Facultative anaerobe, motile, gram-negative, non-pathogenic probiotic strain for treatment of gastrointestinal disorders	Intravenous administration of bacteria expressing azurin (apoptosis inducing protein) decreased the number of lung metastases in orthotopic 4T1 breast cancer in BALB/c mice and restrained growth of subcutaneous B16 melanoma in C57Bl/6 mice (Zhang <i>et al.</i> , 2012b).
<i>Escherichia coli</i> K-12/LLO	Strain expressing <i>hly</i> gene encoding modified listeriolysin (LLO) lacking its N-terminal signal sequence	<i>E. coli</i> MC4100(DE3) modified with plasmid-encoded <i>hly</i> gene for truncated listeriolysin (LLO) in order to facilitate antigen export from phagosome to macrophage cytoplasm for antigen presentation in association with MHC class I. Strain co-expressing LLO and truncated WT1 (Wilms tumor gene 1) induced antitumor effect against WT1-expressing tumors in mice (RMA thymoma and MBL2 leukemia) through induction of CTLs and inhibition of Treg. Paraformaldehyde-fixed bacteria were administered in preventive and therapeutic setting (Dai <i>et al.</i> , 2009).
<i>Listeria monocytogenes</i>	Facultative anaerobe, motile, gram-positive, facultatively intracellular, pathogenic to animals and human, actively escape into cytosol of infected cell	Bacteria-mediated transfer of plasmid DNA into mammalian cells (bactofection) (reviewed by Tangney <i>et al.</i> , 2010). Regression of established transplantable tumors and breaking immune tolerance in genetic tumor models in mice administered with <i>L. monocytogenes</i> <i>dal-</i> , <i>dat-</i> , and <i>actA</i> -deleted strain secreting HPV-16 E7 antigen associated with cervix, head and neck cancer; Her-2/neu breast cancer antigen or prostate specific antigen (PSA) (reviewed by Paterson <i>et al.</i> , 2010). <i>L. monocytogenes</i> HPV-16 E7 (ADXS11-001) = ongoing phase 2 clinical trial for cervical cancer and phase 1 trial for HPV-16+ oropharyngeal carcinoma <sup>2</sup> .
<i>Shigella flexneri</i>	Facultative anaerobe, non-motile, gram-negative, facultatively intracellular, human pathogen	Intravenous injection of <i>S. flexneri</i> M90T <i>aroA</i> mutant strain to mice bearing 4T1 subcutaneous tumors or to spontaneous breast cancer bearing transgenic MMTV-HER2 mice resulted in apoptosis and depletion of tumor associated macrophages (TAMs), which correlated with pronounced 4T1 tumor growth inhibition (Galmbacher <i>et al.</i> , 2010).

<sup>1</sup>Please refer to the NCT01118819 clinical trial listed at ClinicalTrials.gov; <sup>2</sup>Please refer to the ClinicalTrials.gov database and clinical trials no. NCT01266460 and NCT01598792, respectively

fore fully manageable in the clinical setting – therapy can be stopped at the onset of adverse effects or when the bacteria are no longer needed. In fact the use of live biotherapeutics that contain antibiotic resistance genes in clinical trials is not recommended by the regulatory agencies<sup>1</sup>.

<sup>1</sup>Please refer to: *Guidance for Industry: Early Clinical Trials with Live Biotherapeutic Products*, US Food and Drug Administration, 2012; *Environmental Risk Assessments for Medicinal Products containing, or consisting of, Genetically Modified Organisms*, European Medicines Agency, 2007

## Immunostimulation

Bacterial vectors augment the anti-tumor immune response not only because of their cargo but also due to their own potent immunostimulatory activity. A growing tumor creates an immunosuppressive environment and establishes immune escape mechanisms that limit the maturation of dendritic cells (DCs) as well as the priming and migration of specific T cells into the tumor. Bacteria provide a strong danger signal to the immune system. The specific conserved bacterial structures such as components of the cell wall or unmethylated CpG sites in bacterial DNA constitute so-called pathogen-associated

molecular patterns (PAMPs) that are recognized by Toll-like receptors expressed by innate immune cells. PAMPs activate innate- and initiate adaptive immune responses. The induction of TNF, IFN $\gamma$  and IL-12 results in the recruitment and activation of DCs which upon migration to the lymph nodes may efficiently present tumor antigens to T cells (Chorobik & Marcinkiewicz, 2011). It has been shown that indeed microorganisms colonizing tumors and promoting an inflammatory reaction in the tumor microenvironment potentiate the anti-tumor host response (Avogadri *et al.*, 2005).

The unique features of bacterial therapeutics create the opportunity for novel anticancer strategies, that combine tumor-related molecular gradients, natural bacterial features and genetic engineering. Bacteria meet all the requirements for an ideal tumor-targeting agent and might become a novel tool in the anticancer toolbox (Forbes, 2010). A summary of the bacterial strains studied in cancer treatment is shown in Table 1.

### **SALMONELLA HAS A NUMBER OF FEATURES FAVORABLE FOR CANCER THERAPY**

*Salmonella* belongs to the *Enterobacteriaceae* family, a group of Gram-negative, facultatively anaerobic and facultatively intracellular pathogenic bacteria. Currently, based on genome sequence similarity, the genus *Salmonella* is categorized into two species *S. bongori* and *S. enterica* which in turn is divided into six subspecies including *S. enterica* subsp. *enterica* (Tindall *et al.*, 2005). According to the White-Kauffman-Le Minor scheme, the subspecies are classified into more than 2500 serovars by serotyping: O-antigens (polysaccharide domain of the cell surface LPS); H1, H2 antigens (flagellin proteins) and the Vi antigen (Guibourdenche *et al.*, 2010). New classification methods including genome-based techniques are currently under development.

In humans, *Salmonella enterica* subsp. *enterica* serovars Typhimurium and Typhi are causative agents of gastroenteritis and typhoid fever, respectively. There are more than 27 million cases of typhoid fever worldwide each year with a mortality rate of 0.8% resulting from intestinal perforation and peritonitis or severe toxic encephalopathy connected with myocarditis and hemodynamic shock (Parry *et al.*, 2002). Infections with *S. enterica* serovar Typhimurium result in an estimated 94 million cases of gastroenteritis worldwide and 0.16% mortality (Feasey *et al.*, 2012). *S. Typhi* is an exclusively human pathogen, while hosts of *S. Typhimurium* include rodents, poultry and cattle.

*Salmonella Typhimurium* and *Salmonella Typhi* are closely related serotypes of *S. enterica* species which differ in host adaptation and the outcome of infection. Depending on the serotype and host, *Salmonella* colonizes solely the intestinal epithelium leading to gastroenteritis or spreads beyond the gut mainly to liver and spleen causing typhoid fever. *S. Typhimurium* infection in humans is restricted to the digestive tract, with the exception of infants, elderly or immunocompromised individuals in whom it can spread, while in mice *S. Typhimurium* causes enteric fever. On the contrary, *S. Typhi* causes typhoid fever in humans but is not pathogenic to animals. In general, serotypes that lack host specificity, such as *S. Typhimurium*, are more frequently associated with disease in young rather than in adult animals, suggesting their non-optimal adaptation to mature immune system (Baumler *et al.*, 1998).

About 90% of the genes in *S. Typhi* and *S. Typhimurium* serovars are identical (McClelland *et al.*, 2001), but among about 4000 genes of *S. Typhi*, more than 200 are functionally disrupted or inactive, while most of their homologs are still fully functional in *S. Typhimurium*. Genes that differ include virulence factors that determine the pathogenic potential, which can in part explain the restricted host range of *S. Typhi* (McClelland *et al.*, 2001). The majority of virulence factors are encoded by genes grouped in a few clusters in the genome, termed *Salmonella* Pathogenicity Islands (SPIs). *S. Typhimurium* and *S. Typhi* genomes share 11 SPIs, one is specific for *S. Typhimurium* (SPI14) and four are specific for *S. Typhi* (SPI7, 15, 17 and 18) (Kolyva, Waxin, and Popoff, 1992).

*Salmonella sp.* has an ability to multiply inside phagocytic and nonphagocytic cells including macrophages, dendritic cells (DCs), neutrophils, M cells and epithelial cells (Malik-Kale *et al.*, 2011). The ability of *Salmonella* to invade and survive within a host cell is dependent on two Type III Secretion Systems (T3SS), the multiprotein complexes with a needle-like structure present on the bacteria cell wall. Proteins involved in the assembly of the two major T3SSs of *Salmonella* are encoded by SPI1 and SPI2. T3SS1, encoded by SPI1, is required for efficient invasion of nonphagocytic cells. In contrast, the expression of SPI2-encoded T3SS2 is induced following the internalization of *Salmonella* into host cells and is required for post-invasion processes (Velge *et al.*, 2012). During the invasion, some SPI1 encoded proteins such as InvG, InvJ, PrgH, PrgI, PrgK and SpaO are responsible for the assembly of the needle complex, whereas others, including SipB, SipC and SipD, translocate the effector proteins through this needle. Regulation of gene expression in response to the surrounding microenvironment depends on several two-component systems, such as PhoQ/PhoP whose expression is induced by Mg<sup>2+</sup> starvation and low pH (Lucas *et al.*, 2000). Another system, OmpR-EnvZ, responds to changes in osmolarity and regulates invasion (Bajaj *et al.*, 1995) as well as intracellular survival. Upon internalization, *Salmonella* modifies the phagosome into a *Salmonella*-Containing Vacuole (SCV), which is characterized by the presence of some lysosomal membrane proteins, low pH, and transient interactions with the endocytic pathways. At early stages of maturation, SCV recruits and quickly loses early endocytic markers, such as the early endosomal antigen 1 (EEA-1) or transferrin receptor (TfR) (Steele-Mortimer *et al.*, 1999). At later points of maturation it acquires several late endosomal markers, including LAMP1 (Lysosomal-Associated Membrane Protein 1) (Steele-Mortimer, 2008). Bacterial replication is accompanied by the formation of dynamic membrane tubules termed *Salmonella*-Induced Filaments, which extend from SCV throughout the cell (Schroeder *et al.*, 2011). The maturation of SCV is controlled by SPI2-encoded effectors which allow bacteria to avoid phagosome-lysosome fusion and degradation and protect them against reactive oxygen and nitrogen species (Chakravorty *et al.*, 2002; Janssen *et al.*, 2003).

After the ingestion of *S. enterica*, the bacteria use different routes to cross the intestinal barrier. The main route leads through the receptor-mediated endocytosis by microfold cells (M-cells) in Peyer's patches (Jepson & Clark, 2001), independently of SPI1 and SPI2 (Martinez-Argudo & Jepson, 2008). Then the bacteria are taken up by the underlying macrophages. Enterocytes of the intestinal epithelium, except for the M cells, engulf *Salmonella* by macropinocytosis in a SPI1-dependent manner. The

bacteria can be also engulfed by DCs (Swart & Hensel, 2012). In epithelial cells *S. Typhimurium* can reside and replicate in SCV, as well as in the cytosol (Malik-Kale *et al.*, 2012); however, these two intracellular populations of bacteria are transcriptionally distinct: the intravacuolar bacteria are SPI2-induced, while the cytosolic bacteria are SPI1-induced and flagellated (Knodler *et al.*, 2010). *Salmonella* induces caspase-1 and -2 mediated apoptosis of infected macrophages and epithelial cells (Jesenberger *et al.*, 2000; Kim *et al.*, 1998; Monack *et al.*, 1996). Apoptosis depends mainly upon the SPI1 effector protein, SipB, delivered to the host cell by SPI1-encoded T3SS (Jesenberger *et al.*, 2000). Bacteria, engulfed by macrophages and DCs spread from Peyer's patches to mesenteric lymph nodes, spleen and liver. The ability of *Salmonella* to elicit systemic disease is serovar-dependent and correlates with its capability to survive and replicate inside the host cell and to avoid the host adaptive immune response (reviewed by Swart & Hensel, 2012).

### THERAPEUTIC SALMONELLA STRAINS ARE DERIVED FROM *S. TYPHIMURIUM* OR *S. TYPHI*

*S. Typhimurium* infection in mice remains the dominant animal model of typhoid fever because it leads to comparable systemic disease with dissemination of bacteria to the lymphatic system and peripheral organs. Hence the prevalence of *S. Typhimurium*-based tumor therapeutic vectors studied in murine models of cancer. The choice of *S. Typhimurium* over *S. Typhi* for pre-clinical research on cancer therapy could be arguable but is legitimated by the availability of suitable animal models. Some improvement was made by the development of a transgenic mouse model of *S. Typhi* infection (Song *et al.*, 2010), but it has not been applied to *Salmonella*-based tumor therapy studies yet. Nevertheless, a superior induction of immune response to heterologous antigen delivered by an orally administered vaccine strain of *S. Typhimurium* over *S. Typhi* was shown in a clinical trial (Angelakopoulos & Hohmann, 2000). Both serotypes are amenable to genetic modifications of virulence and in terms of safety are equally eligible as live attenuated therapeutic strains. There has already been some success in the clinical use of attenuated *Salmonella* strains. *S. Typhimurium* VNP20009 was shown to be safe when administered to cancer patients (Toso *et al.*, 2002) and *S. Typhi* Ty21a, a live attenuated oral vaccine against typhoid fever, has already been applied for more than 30 years to adults and children above 6 years of age who are at risk of *S. Typhi* exposure. A phase I clinical trial evaluating the safety, tolerability, and effects of the *S. Typhi* Ty21a strain used as a DNA delivery vehicle in cancer patients has been announced (Niethammer *et al.*, 2012) but its results are not yet available.

Attenuation of virulence is crucial for the development of new *Salmonella*-based vector strains in order to elicit an appropriate profile of the immune response. Up to date about 50 genes of *Salmonella* spp. have been proven to be feasible for inactivation in order to obtain an attenuated derivative with modified virulence or metabolic functions. Gene inactivation is achieved by laboratory selection of the desired phenotype, for example by passaging bacteria through selective conditions and screening for survivors, or is the result of site-directed or chemical mutagenesis. Inactivation of genes coding for proteins involved in metabolic pathways generates auxotrophic strains, i.e. dependent on external sources of nutrients, for example aromatic amino acids (*aro* mu-

tants) or purines (*pur* mutants). Direct attenuation of virulence involves inactivation of genes encoding proteins interacting with the infected organism or factors regulating their expression. The latter include: (i) *phoP* and/or *phoQ*, which regulate expression of many genes, e.g. those contributing to the resistance against antimicrobial peptides and genes located in pathogenicity islands, (ii) *cya* and *crp* genes coding for global regulatory factors involved in expression of many proteins of cellular catabolism, (iii) *htrF* gene, which enables survival under stress conditions (Garmory *et al.*, 2002; Raupach & Kaufmann, 2001; Raupach *et al.*, 2003). The attenuating mutations introduced into *Salmonella* experimental strains are summarized in Table 2.

An interesting example comes from a sophisticated work of Robert Hoffman's group: A1-R is an auxotrophic *Salmonella* strain developed for increased tumor targeting and limited toxicity. First, the researchers obtained an A1 auxotrophic strain dependent on an external source of leucine and arginine by nitrosoguanidine (NTG) mutagenesis of *S. Typhimurium* 14028-GFP. To further enhance tumor targeting of *S. Typhimurium* A1, bacteria were injected *i.v.* into nude mice bearing HT-29 human colon adenocarcinoma. GFP-expressing bacteria isolated from the excised infected tumors, were termed A1-R and had an increased ability to adhere to cancer cells; the number of A1-R bacteria attached to HT-29 cells *in vitro* was approximately six times higher than that of the parental A1 strain (Zhao *et al.*, 2006).

*S. Typhimurium* A1-R was tested in numerous human tumor xenografts in nude mice, such as MARY-X breast tumor (Zhao *et al.*, 2006), orthotopic prostate PC-3 cancer (Zhao *et al.*, 2007), orthotopic human pancreatic cancer (Nagakura *et al.*, 2009), orthotopic U87 spinal cord glioma (Kimura *et al.*, 2010), orthotopic MDA-MB-435 breast cancer (Zhang *et al.*, 2012a), lung fibrosarcoma (Hayashi *et al.*, 2009b) and lung osteosarcoma (Hayashi *et al.*, 2009a) resulting in a significant tumor growth inhibition in all tested models, with complete tumor regression in a few of them.

Applicability of A1-R in metastatic disease has also been tested. Hayashi *et al.* (2009b) developed a lymph node metastasis model of human pancreatic cancer (XPA-1) by injecting XPA-1 cells into the inguinal lymph node of nude mice which resulted in tumor growth in the axillary lymph node. Five of six mice had their lymph node metastases eradicated within 7–21 days after intravenous treatment with A1-R in contrast to growing metastases in the untreated control group (Hayashi *et al.*, 2009b).

A1-R has also been tested in immunocompetent mice bearing murine Lewis lung carcinoma (Tome *et al.*, 2013). The authors proposed to apply a priming dose of  $1 \times 10^6$  cfu followed, 4 hours later, by a therapeutic dose of  $1 \times 10^7$  cfu of A1-R. The priming dose resulted in an elevated serum level of TNF and tumor vessel destruction, which could facilitate the invasion of tumor by bacteria.

As it can be expected, the mode of attenuation affects the quality of the anti-*Salmonella* immune response. While cytokines of the Th1 type (IFN $\gamma$ , IL-12, IL-18) are crucial for protection against *Salmonella* in mice and humans, different mutant *Salmonella* strains require alternative cytokines for the control of infection. Studies with knock-out mice showed that IFN $\gamma$  and TNF were essential for the early control of infection with both wild type and *aroA* mutant strains. In contrast, TNF was not required for the clearance of the *aroA* mutant (Raupach & Kaufmann, 2001).

Table 2. Attenuated strains of *S. Typhimurium* developed as bacterial vaccine vectors.

Parental strain	Modified strain	
ATCC 14028	A1-R	leucine and arginine auxotrophs (Zhao <i>et al.</i> , 2005)
SL1344	BRD509	<i>aroA aroD</i> aromatic compound dependent (Strugnell <i>et al.</i> , 1992)
NCTC12023 (ATCC 14028)	MvP728	<i>purD htrA</i> adenine dependent; defective intra-macrophage survival (Xiong <i>et al.</i> , 2010)
Not stated	Re88	<i>aroA dam</i> (Xiang <i>et al.</i> , 2001) DNA adenine methylase mutants are defective in protein secretion, cell invasion and M cell cytotoxicity
SL3261	SB824	<i>aroA sptP</i> (encodes virulence protein SptP) (Panthel <i>et al.</i> , 2005)
14028s	SHJ2037	<i>relA spoT</i> (genes that encode ribosome-bound and cytosolic ppGpp synthetase, respectively) accumulates in infarcted myocardium due to defective ppGpp synthesis ( $\Delta$ ppGpp) (Song <i>et al.</i> , 2010)
SL1346	SL3261	<i>aroA</i> (Meng <i>et al.</i> , 2010)
2337-65 (WRAY)	SL7207	<i>aroA</i> dependent on <i>p</i> -aminobenzoate and 2,3-dihydroxybenzoate for the synthesis of aromatic amino acids; these two compounds are not available in a mammalian host (Hoiseith & Stocker, 1985)
ATCC 14028	VNP20009 (YS1646)	<i>msbB purI</i> purine dependent; reduced ability to induce septic shock due to altered lipid A structure (Low <i>et al.</i> , 2004)
SL7207	YB1	<i>aroA</i> modified to express <i>asd</i> essential gene under hypoxia-induced promoter (Yu <i>et al.</i> , 2012)
UK-1	X4550	<i>cya crp asd</i> (Saltzman <i>et al.</i> , 1996) adenylate cyclase and cyclic AMP receptor protein mutants are avirulent in mice

Attenuated *Salmonella* strains preferentially colonize solid tumors and inhibit their growth in animal models (Bermudes *et al.*, 2002; Pawelek *et al.*, 1997; Zhao *et al.*, 2005). In some therapeutic approaches attenuated strains were used without any further modifications to exert tumor-directed cytotoxic effects and induce proper anti-tumor immune response. Apart from the A1-R strain described above also the application of the *S. Typhimurium* X9241 strain brought successful results. Bacteria injected intratumorally to CT26 tumors or CT26 tumors expressing human tumor antigen, Her-2/neu, significantly inhibited tumor growth. Surprisingly, they did not potentiate tumor-antigen-specific cellular immunity. However, they induced an important functional shift in the phenotype of tumor-infiltrating CD11b<sup>+</sup>Gr-1<sup>+</sup> subpopulation of leukocytes (myeloid derived suppressor cells, MDSC) towards immunogenic TNF-secreting neutrophils. Moreover, the therapy reduced the percentage of regulatory T cells which may promote tumor development (Hong *et al.*, 2013).

Thanks to the intracellular lifestyle and immunomodulatory properties attenuated *Salmonella* strains are also used as vectors for the delivery of therapeutic molecules. The cargo is a genetic material which codes for proteins including tumor antigens (described in the next chapter), cytokines, apoptosis-inducing factors, prodrug-converting enzymes, or short hairpin RNAs (shRNAs) able to silence expression of a protein of choice. Numerous approaches were developed to enhance and navigate the immunomodulatory properties of *Salmonella* through genetic modifications that ensure the delivery of proapoptotic molecules or cytokines straight to the tumor, which limits their potential undesired systemic side effects. The examples are listed in Table 3.

The group of John C. Reed demonstrated a significant increase in tumor growth inhibition by a *Salmonella* strain

expressing IL-18 in immunocompetent mice (Loeffler *et al.*, 2008). The modified and parental strains showed comparable toxicity limited to the spleen and liver. IL-18 stimulates T cell and NK cell to proliferation, cytotoxicity and cytokine production. Administration of IL-18-secreting *Salmonella* did not improve tumor infiltration by CD8<sup>+</sup> T lymphocytes but led to increased infiltration by granulocytes, CD4<sup>+</sup> T cells and DX5<sup>+</sup> NK cells, when compared to *Salmonella* control strain (Loeffler *et al.*, 2008).

In order to enhance the proapoptotic activity of *S. Typhimurium* towards infected cancer cells several research groups took an advantage of apoptosis-inducing factors and equipped bacteria with appropriate expression vectors. TRAIL (TNF-related apoptosis-inducing ligand) has a capacity to selectively induce apoptosis in a wide variety of cancer cells but hardly in normal cells which makes it a promising cancer therapeutic (Hylander *et al.*, 2005; Shanker *et al.*, 2008; Walczak *et al.*, 1999; Yagita *et al.*, 2004). Similarly to TNF, TRAIL exerts its proapoptotic effect through the death receptor-dependent pathway which activates the caspase cascade (LeBlanc & Ashkenazi, 2003).

Ganai *et al.* (2009) constructed an expression vector placing *TRAIL* under the promoter of *recA* gene involved in the prokaryotic SOS response to DNA damage (Anderson & Kowalczykowski, 1998). It created a radiation-inducible system, where expression of TRAIL was turned on by genotoxic damage evoked by radiation. Such a system enables temporal and spatial control of the gene expression, additionally increasing the selectivity of the therapy towards cancer cells subjected to radiotherapy. Intravenous administration of *S. Typhimurium* VNP20009 equipped with a *PrecA*-TRAIL construct (VNP/pRE-TR) into Balb/c mice bearing subcutaneous 4T1 mammary carcinoma followed by 2 Gy whole body

Table 3. Therapeutic approaches based on *S. Typhimurium* modified to deliver apoptosis inducing or immune modulatory factors.

Vector	Cargo	Mouse strain		Therapeutic scheme	
BRD509	cDNA for TNF fused to 160 amino acid residue-N-terminal fragment of SipB under the control of bacterial <i>lac</i> promoter	C57Bl/6	s.c. TC-1 cervical tumor, B16F10 melanoma	Two s.c. injections of 10 <sup>8</sup> CFU/mouse 7 and 14 days after s.c. inoculation of 10 <sup>5</sup> B16F10	Complete inhibition of tumor cell growth in 90% of animals, but these mice were not protected against second B16F10 challenge. Reduced growth of all listed tumors, although with diverse efficacy (Yoon <i>et al.</i> , 2011)
		BALB/c	s.c. 4T-1 breast cancer, CT26 colon cancer, and RENCA kidney carcinoma		
SL7207	TRAIL and apoptin genes under the control of eukaryotic promoters	BALB/c nude	s.c. SGC-7901 human gastric cancer (5 × 10 <sup>5</sup> cells)	Intratumoral injection 7 days after tumor implantation, repeated every 7 days (2 × 10 <sup>6</sup> CFU)	Cancer cell apoptosis in tumor tissue and tumor regression (Cao <i>et al.</i> , 2010)
VNP20009 and MVP728	Stat3 shRNA and survivin expressing plasmid	C57Bl/6	s.c. B16F10 melanoma (10 <sup>5</sup> cells)	YS1646 with Stat3 shRNA <i>i.v.</i> injected at 10 <sup>7</sup> CFU when tumor volumes were 50 mm <sup>3</sup> or above (7–8 mm diameter), followed by oral gavage with 10 <sup>7</sup> CFU of MVP728 with survivin expression plasmid	Enhancement of CD4+ and CD8+ T lymphocytes infiltration into tumors, increased tumor cell apoptosis, suppression of s.c. B16F10 melanoma growth (Manuel <i>et al.</i> , 2011)
VNP20009	cDNA for IL-18 fused to N-terminal leader sequence for directing secretion, under the control of bacterial <i>ompC</i> promoter	BALB/c	s.c. CT26 colon carcinoma (10 <sup>5</sup> cells)	<i>i.v.</i> injection of 5 × 10 <sup>6</sup> CFU when tumors were visible (14 days after inoculation)	Reduced tumor growth, leukocyte infiltration into tumors, increased intratumoral level of IL-1β, TNF, IFNγ
		BALB/c	s.c. D2F2 breast carcinoma (2.5 × 10 <sup>5</sup> cells)	<i>i.v.</i> injection of 5 × 10 <sup>6</sup> CFU on day 9, 14 and 19 after tumor inoculation	Significant tumor growth inhibition
		C57Bl/6	<i>i.v.</i> Lewis lung carcinoma (5 × 10 <sup>4</sup> cells)	<i>i.v.</i> injection 6, 13, and 20 days after tumor cells injection	Reduced tumor burden in lungs (Loeffler <i>et al.</i> , 2008)
VNP20009	IDO shRNA (immunosuppressive molecule indoleamine 2,3 dioxygenase 1)	C57Bl/6	s.c. B16F10 melanoma (2.5 × 10 <sup>5</sup> cells)	2.5 × 10 <sup>6</sup> CFU injected intravenously twice, 4 days apart, into mice with tumor diameters equal or greater than 7 mm	Synergistic effect of IDO silencing and <i>S. Typhimurium</i> on tumor growth suppression. Increased tumor influx of PMNs and intratumoral cell death. Tumor growth suppression occurred also in the absence of functional adaptive immunity (Blache <i>et al.</i> , 2012)
VNP20009	TRAIL under the control of bacterial anaerobic-inducible <i>nirB</i> promoter	C57Bl/6	s.c. B16F10 melanoma (5 × 10 <sup>5</sup> cells) and RM-1 prostate cancer (2 × 10 <sup>5</sup> cells)	<i>i.p.</i> injection of 10 <sup>5</sup> CFU per mouse on day 7 for B16F10 or day 9 for RM-1 after tumor inoculation	Increased levels of TRAIL in B16F10 tumor but not in liver or spleen and tumor growth inhibition. VNP-TRAIL was not more effective in tumor growth suppression of TRAIL-resistant RM-1 tumors than VNP control strain (Chen <i>et al.</i> , 2012)
VNP20009	CCL21 under the control of bacterial <i>ompC</i> promoter	BALB/c	s.c. CT26 colon carcinoma (2.5 × 10 <sup>5</sup> cells)	Intravenous injection 9, 14 and 19 days after tumor inoculation	Significantly inhibited growth of subcutaneous tumors and pulmonary tumor foci (Loeffler <i>et al.</i> , 2009)
			<i>i.v.</i> D2F2 breast carcinoma (5 × 10 <sup>4</sup> cells) for pulmonary tumor model	<i>i.v.</i> injection of 5 × 10 <sup>6</sup> CFU at day 6, 13, and 20 after tumor cells injection	

γ-irradiation 2 days later resulted in a significant decrease in tumor growth. The combined treatment increased the tumor size doubling time by 50% compared to VNP/pRA-TR treatment alone and by 100% in comparison to PBS control. The combined therapy has a synergistic effect since irradiation alone barely influenced tumor growth (Ganai *et al.*, 2009).

A similar approach was exploited by Chen *et al.* (Chen *et al.*, 2012) who placed TRAIL cDNA under the control of *nirB* promoter induced by hypoxic conditions (Chatfield *et al.*, 1992). The *S. Typhimurium* VNP20009 strain carrying TRAIL expression vector was intraperitoneally administered to B16F10 melanoma-bearing C57BL/6 mice. Significant inhibition of melanoma tumor growth

and extended survival time were observed. The TUNEL assay showed that the therapeutic effect of modified bacteria was associated with a significant increase in apoptosis of melanoma cells compared to mice receiving the control strain. Importantly, the immunohistochemical study revealed that indeed TRAIL was preferentially expressed in the hypoxic, necrotic area of the tumor, and not in the oxygenated liver or spleen, which may explain limited toxicity of TRAIL in normal tissues.

It has been shown that Smac (second mitochondria-derived activator of caspases) is involved in TRAIL-induced apoptosis and may affect the efficiency of TRAIL-based therapies (Deng *et al.*, 2002; Zhang *et al.*, 2001). Also *in vivo* studies showed that complete regression of established glioma in a mouse model was achieved only when TRAIL therapy was associated with Smac administration (Fulda *et al.*, 2002; Pei *et al.*, 2004). Fu *et al.* (2008) took an advantage of this observation and engineered a modified *S. Typhimurium* SL3261 strain carrying a dual-gene vector coding for both Smac and TRAIL. The cDNAs were placed under the promoter of human telomerase reverse transcriptase, highly active in majority of cancers and generally inactive in normal differentiated cells (Kim *et al.*, 1998). LL/2 Lewis lung carcinoma, B16F10 melanoma and 4T1 mammary carcinoma cells infected with the modified bacteria showed high expression levels of both proteins accompanied by a high rate of apoptosis. Moreover, oral administration of the modified strain significantly suppressed tumor growth in all tested mice models (LL/2, B16F10, 4T1), without any observable side-effects. The volumes of the tumors were lowered approximately by 65–75% compared to groups treated with a control strain and by 90% compared to PBS-treated animals.

Cao *et al.* (2010) applied combination of TRAIL with another apoptosis-inducing factor — apoptin (VP3), a protein of the chicken anemia virus proved to promote tumor cell-specific apoptosis in a p53-independent manner (Zhuang *et al.*, 1995). The study showed that intratumoral administration of *S. Typhimurium* SL7207 carrying apoptin and TRAIL coding sequences under the control of eukaryotic cytomegalovirus immediate early promoter to human gastric tumor xenografts in nude mice resulted in increased effectiveness of bacteria-mediated tumor growth suppression, with complete tumor regression in some animals. TUNEL assays in tissue sections showed a higher apoptotic rate in mice treated with *S. Typhimurium* SL7207 carrying apoptin and TRAIL genes compared to a control strain (Cao *et al.*, 2010).

### SALMONELLA CAN BE ALSO USED AS A TUMOR VACCINE VECTOR

The vast majority of tumors express proteins or other antigens that are absent (or present only in very low quantities) in healthy adult tissues. These tumor-associated antigens (TAAs) are potentially immunogenic and tumor development is usually accompanied by specific, although often ineffective, anti-TAA immune response. TAA vaccines used for cancer therapy often fail, probably due to inadequate antigen presentation and insufficient activation of innate immunity. The application of *Salmonella* as a vector for TAAs should result in overcoming both impediments. The first attempts to deliver TAA via *Salmonella* were undertaken in late 1990s. From that time numerous studies utilizing natural (mPSCA, mAFP, survivin, endoglin) or artificial ( $\beta$ -galactosidase) tumor antigens have proved that placing a TAA-coding

transgene under strong cytomegalovirus promoter in a plasmid carried by *Salmonella* allows for TAA expression in the cytoplasm of infected cells or dendritic cells which engulfed the infected, apoptotic cells (Paglia *et al.*, 1998; Yrlid & Wick, 2000); TAA expression elicits efficient cell-mediated or both cell-mediated and humoral immune responses (Ahmad *et al.*, 2011; Chou *et al.*, 2006; Fest *et al.*, 2009; Huebener *et al.*, 2008; Jarosz *et al.*, 2013; Paglia *et al.*, 1998). However, this is not always the case. The group of Dai-Ming Fan transformed *Salmonella* with a plasmid, which expressed a fusion protein consisting of a mimotope of the gastric tumor antigen, MG2 with either PADRE T helper epitope (Guo *et al.*, 2003) or HBcAg, a strong Hepatitis B virus T-cell-dependent and T-cell-independent antigen (Meng *et al.*, 2005). Although oral administration of either *Salmonella* strain resulted in a partial inhibition of the growth of the subsequently injected Ehrlich ascites carcinoma, only the humoral but not the cell-mediated response against MG2 could be detected (Guo *et al.*, 2003; Meng *et al.*, 2005).

It is believed that intracellular location of *Salmonella* within phagosomes may limit the ability to generate a MHC class I-restricted immune response towards transgene-encoded proteins. However, *Salmonella* expresses a multi-protein complex, T3SS, to deliver some bacterial effector proteins into the host cell in order to modulate its functions and create a microenvironment favorable for bacterial survival and proliferation (Galan & Collier, 1999). A special N-terminal signal sequence directs bacterial proteins for export through T3SS to the host cell cytoplasm. This very mechanism was employed by several research groups to deliver *Salmonella* plasmid-encoded tumor antigens to the host cell cytoplasm and thus make them available for the MHC class I presentation. Instead of sequences encoding TAAs alone, the constructs coding for chimeric proteins consisting of a tumor antigen preceded by an N-terminal fragment of a bacterial protein subjected to T3SS export (containing secretion and translocation signals) were placed in the *Salmonella* plasmid. These included peptides derived from the SopE, SseF and YopE proteins (Jellbauer *et al.*, 2012; Manuel *et al.*, 2011; Nishikawa *et al.*, 2006; Zhu *et al.*, 2010). The chimeric transgenes were usually placed under bacterial promoters activated after invasion of the host cell.

This approach was applied by Nishikawa *et al.* in an attempt to generate a therapeutic vaccine against cancers overexpressing the NY-ESO-1 antigen (Nishikawa *et al.*, 2006). This germ cell antigen seems to be a proper target for immunotherapy, since it is expressed by a broad variety of tumors but not by normal somatic cells. Following oral administration of the *Salmonella*-based vaccine that delivered NY-ESO-1 and assured its cytoplasmic localization, CD8<sup>+</sup> T cell-dependent regression of established NY-ESO-1-expressing tumors was observed. What is more, the vaccine was able to initiate a process known as epitope spreading and was therefore effective even towards tumors lacking the NY-ESO-1 antigen. Intratumoral injection of this *Salmonella* strain delivering the antigen and engaging pre-existing NY-ESO-1-specific CD8<sup>+</sup> T cells resulted in tumor regression and activation of subsets of T cells recognizing at least two different tumor antigens that were not delivered by *Salmonella* (Nishikawa *et al.*, 2006).

A more complex transgene was introduced into a *Salmonella* plasmid by Zhu *et al.*, who worked on an efficient anti-melanoma vaccine (Zhu *et al.*, 2010). It encoded a fusion protein consisting of the secretion and translocation signals of SopE and a fragment of the



melanoma-specific TRP2 (tyrosinase-related protein 2) antigen containing three immunodominant epitopes. The presence of Hsp70, often referred to as immunochaperone, facilitates the proper presentation of antigenic peptides to cytotoxic T cells and may therefore enhance the anti-melanoma immune response. This vaccine induced a specific CTL response against B16F10 melanoma and showed strong protective as well as therapeutic effects (Zhu *et al.*, 2010).

Another modification aiming in augmenting the presentation of *Salmonella*-delivered neuroblastoma antigens was proposed by the group of Lode (Fest *et al.*, 2009; Huebener *et al.*, 2008). The chimeric protein encoded by *Salmonella* plasmid contained a stably ubiquitinated tumor antigen, either tyrosine hydroxylase- (Huebener *et al.*, 2008) or survivin (Fest *et al.*, 2009) fragments. The presence of ubiquitin guaranteed proteasomal degradation of proteins encoded by the transgenes and increased MHC I-mediated peptides presentation. This approach led to significant CD8<sup>+</sup> T cell-dependent inhibition of neuroblastoma growth (Fest *et al.*, 2009; Huebener *et al.*, 2008) and decreased the rate of metastasis (Huebener *et al.*, 2008) or tumor growth upon rechallenge (Fest *et al.*, 2009).

Manuel *et al.* also chose survivin as an excellent target for tumor therapy (Manuel *et al.*, 2011). This anti-apoptotic protein is expressed at a low level in normal adult tissues but is abundant in essentially all solid tumors (Altieri, 2003), as well as in endothelial cells during angiogenesis (Tran *et al.*, 1999). However, unlike their predecessors, the researchers utilized bacterial promoter to express a codon-optimized transgene in *Salmonella* and used the SseF secretion signal to transport survivin to the cytoplasm of the infected cells. The combined therapy consisting of sequential intravenous injection of two *Salmonella* strains: the first encoding shRNA targeting a tolerogenic transcription factor, and the second coding for SseF-survivin, turned out to be effective even in the case of large, well-established melanoma tumors. The silencing of STAT3 expression, crucial for this very promising result, led to increased proliferation of intratumoral CD4<sup>+</sup> and CD8<sup>+</sup> T cells and elevated levels of granzyme B (Manuel *et al.*, 2011).

Not only survivin but also other proteins overproduced in endothelium during angiogenesis, such as VEGFR2, one of the VEGF receptors, or endoglin, a component of the TGFβ (Transforming Growth Factor beta) receptor complex, have been chosen as targets for *Salmonella*-based vaccines (Jarosz *et al.*, 2013; Jellbauer *et al.*, 2012). The induction of the CTL response against these antigens should reduce angiogenesis and destroy tumor vasculature leading to inhibition of tumor development. Indeed, *Salmonella* carrying a plasmid encoding a fusion protein comprising the YopE secretion sequence and the fragment of VEGFR2 containing the CD8<sup>+</sup> T-cell epitope efficiently limited the growth of B16F10 melanoma in both prophylactic and therapeutic settings (Jellbauer *et al.*, 2012). The authors hypothesized that the vaccine may also affect the immunosuppressive tumor microenvironment by destroying the VEGFR2-positive subset of Treg lymphocytes.

Similarly, a combined therapy using orally applied *Salmonella* carrying endoglin cDNA with an intratumorally injected plasmid coding for interleukin-12 reduced microvessel density and diminished the number of Tregs within B16F10 tumors resulting in inhibition of the tumor growth and prolonged survival of mice (Jarosz *et al.*, 2013).

Some examples of *in vivo* studies on the efficacy of various *Salmonella* Typhimurium-based anti-cancer vaccines are presented in Table 4.

Recently, a phase 1 clinical trial evaluating the safety of the first *Salmonella* Typhi-based oral vaccine coding for the full length human VEGFR2 and aimed at eliciting an anti-VEGFR2 immune response has started and involves patients suffering from pancreatic cancer. The results of this trial are not yet available (Niethammer *et al.*, 2012).

#### CLINICAL STUDIES INDICATE TUMOR TARGETING AS THE MAJOR LIMITATION OF SALMONELLA-BASED THERAPIES

The mouse is a natural host for *Salmonella enterica* serovar Typhimurium and this species is considered to be the most sensitive to VNP20009 infections. However, the maximum tolerated dose (MTD) of VNP20009 in mice is large and was estimated to be  $0.5 \times 10^8$  colony forming units per kg of body weight, which makes this attenuated strain at least 50 000 times less virulent than the parental *Salmonella* (Lee *et al.*, 2000). Importantly, similar values of MTD were estimated for other species — dogs, pigs and monkeys ( $3.0 \times 10^7$ ,  $1.9 \times 10^8$  and  $2.5 \times 10^8$  cfu/kg, respectively). Most of the adverse effects observed were transient and related to physiological responses to infection and stress, rather than to the intrinsic toxicity of the bacterial treatment. The studies in pigs found no endotoxic or septic shock reactions. In tumor-bearing mice, VNP20009 accumulates preferentially in tumors over livers at a ratio of 1000:1, but also in dogs with spontaneous neoplasia tumor colonization was detectable in 10 out of 24 *Salmonella*-treated cases (42%) (Thamm *et al.*, 2005). Those promising features of preferential localization and apparent lack of toxicity allowed VNP20009 to enter clinical development in 1999.

In the first-in-man study performed by Vion Pharmaceuticals Inc., a total of 25 patients — 24 with metastatic melanoma and one with metastatic renal cancer — were treated with 30-minute intravenous bolus infusions of VNP20009 dose ranging from  $10^6$  to  $10^9$  cfu/m<sup>2</sup>. On the basis of dose-limiting toxicity symptoms, the MTD of VNP20009 in humans was estimated to be  $3.0 \times 10^8$  cfu/m<sup>2</sup>. Adverse reactions at higher doses included fever, hypotension, anemia and thrombocytopenia and were probably due to cytokine release. Despite VNP20009 attenuation, significant amounts of TNF were detected in the patients' peripheral blood. Most adverse effects were mild and rapidly reversible, but none of the 25 patients experienced objective cancer regression. Bacteria were rapidly cleared from the peripheral blood and tumor colonization by *Salmonella* could be detected only in three patients (Toso *et al.*, 2002). This result was clearly in contrast with data from the murine tumor models.

In a subsequent clinical study, additional 4 patients with metastatic melanoma received a 4-hour intravenous infusion of VNP20009 at the MTD of  $3.0 \times 10^8$  cfu/m<sup>2</sup>. Adverse effects of the treatment included fever, chills and nausea, but were minor and transient. VNP20009 was detectable in samples of patients' blood up to 2 hours post treatment. No *Salmonella* could be cultured from tumor biopsies taken within 2 weeks of therapy (Heimann & Rosenberg, 2003).

The results of VNP20009 phase I clinical trials did not confirm *Salmonella* accumulation and tumor regression similar to previous preclinical data. However, the important finding is that VNP20009 can be safely ad-

Table 4. Applications of *S. Typhimurium* as a vaccine vector

Plasmid containing:	Promoter	<i>Salmonella</i> strain	Tumor	Mouse strain	Route*	P/T**	References
Beta-galactosidase ( $\beta$ -gal)	CMV	SL7207	$\beta$ -gal <sup>+</sup> -F1A11 fibrosarcoma	Balb/c	O	P	(Paglia <i>et al.</i> , 1998)
MG7-Ag-mimotope-PA-DRE (T <sub>H</sub> -epitope)	CMV	SL3261	Ehrlich ascites carcinoma	Balb/c	O	P	(Guo <i>et al.</i> , 2003)
MG7-Ag-mimotope-HBcAg	CMV	X4550	Ehrlich ascites carcinoma	Balb/c	O	P	(Meng <i>et al.</i> , 2005)
mAFP	CMV	Not stated	CT26-mAFP colon carcinoma Hepa1-6 hepatoma	Balb/C C57J/L	O	P	(Chou <i>et al.</i> , 2006)
<u>SopE</u> -NY-ESO-1***	Psop	$\Delta$ phoP $\Delta$ phoQ	CMS5a sarcoma	Balb/c	O IT	T	(Nishikawa <i>et al.</i> , 2006)
Tyrosine hydroxylase epitopes-Ub	CMV	SL7207	NXS2 neuroblastoma	A/J	O	P + T	(Huebener <i>et al.</i> , 2008)
Survivin epitopes-Ub	CMV	SL7207	NXS2 neuroblastoma	A/J	O	P + T	(Fest <i>et al.</i> , 2009)
<u>SopE</u> -Hsp70-Trp2	Psop	SL3261	B16F10 melanoma	C57BL/6J	O	P + T	(Zhu <i>et al.</i> , 2010)
<u>SseF</u> -CO-Survivin**** + STAT3shRNA	PsseA	MVP728 YS1646	B16F10 melanoma	C57BL/6	O	T	(Manuel <i>et al.</i> , 2011)
mPSCA	CMV	SL7207	TRAMPC1 prostate carcinoma	C57BL/6	O	P	(Ahmad <i>et al.</i> , 2011)
<u>YopE</u> -VEGFR2	Plac	SB824	B16F10 melanoma	C57BL/6	OG	P	(Jellbauer <i>et al.</i> , 2012)
Endoglin	CMV	SL7207	B16F10 melanoma Renca renal carcinoma	C57BL/6 Balb/c	O	P + T	(Jarosz <i>et al.</i> , 2013)

\*O, oral; OG, orogastric; IT, intratumoral; \*\*P, prophylactic-, T, therapeutic approach; \*\*\*underlined, *Salmonella* protein fragments serving as secretion signals; \*\*\*\*CO, codon optimized.

ministered to humans in large doses and that the toxicity of this bacterial strain is limited. Moreover, the first-in-man study revealed that low tumor targeting in humans is a crucial therapeutic drawback of VNP20009. Since this feature can be significantly improved using genetic engineering, we made an attempt to enhance the accumulation of *Salmonella* in human tumors by constructing a VNP20009 strain expressing single chain antibody fragments specific to the carcinoembryonic antigen (CEA; Fig. 1). This VNP derivative was able to efficiently target CEA-expressing tumors in mice and could possibly overcome the targeting limitations of VNP20009 in humans, since CEA is present on more than 50% of human carcinomas (Bereta *et al.*, 2007).

In summary, bacterial cancer therapy has recently moved beyond an interesting concept and has by now been supported by solid preclinical and clinical data. The unique features of bacterial therapeutics create the opportunity for novel anticancer strategies as bacteria meet all requirements for an ideal tumor-targeting agent. While the mechanism of action is often unclear, many examples have already proved that cancer treatment with bacteria can be site-specific, highly focused on the tumor and safe to other tissues. Among bacterial strains evaluated as cancer therapeutics so far, *Salmonella* Typhimurium is

one of the most promising with first-in-man studies that support feasibility of clinical application. However, excellent tumor colonization observed in murine models was not confirmed in humans, suggesting that tumor targeting is the major obstacle for further development. As




Figure 1. Tumor targeting of *Salmonella* via the anti-CEA antibody fragment.

(A) a single chain antibody fragment (scFv) specific to carcinoembryonic antigen (CEA) was derived from a CEA-specific immunoglobulin G molecule; (B) A DNA sequence encoding scFv was fused with the gene coding for OmpA, an outer membrane protein of *E. coli*, and expressed in VNP20009, an attenuated strain of *Salmonella* Typhimurium.

many researchers focus on the effector molecules and other antitumor features of *S. Typhimurium*, insufficient localization in human tumors remains to be an unsolved issue. Targeting based on an antibody-fragment specific to TAAs is one of the few approaches proposed to overcome this drawback of therapeutic *Salmonella* strains.

### Acknowledgements

The authors gratefully acknowledge financial support from the Polish National Centre for Research and Development through INNOTECH grant no. 152553 INNOTECH grant no. 152553 and the funding from the Jagiellonian University within the SET project cofinanced by the European Union.

### REFERENCES

Ahmad S, Casey G, Cronin M, Rajendran S, Sweeney P, Tangney M, O'Sullivan GC (2011) Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen. *J Urol* **186**: 687–693.

Alexandroff AB, Jackson AM, O'Donnell MA, James, K (1999) BCG immunotherapy of bladder cancer: 20 years on. *Lancet* **353**: 1689–1694.

Altieri DC (2003) Validating survivin as a cancer therapeutic target. *Nat Rev Cancer* **3**: 46–54.

Anderson DG, Kowalczykowski SC (1998) Reconstitution of an SOS response pathway: derepression of transcription in response to DNA breaks. *Cell* **95**: 975–979.

Angelakopoulos H, Hohmann EL (2000) Pilot study of phoP/phoQ-deleted *Salmonella enterica* serovar *typhimurium* expressing *Helicobacter pylori* urease in adult volunteers. *Infect Immun* **68**: 2135–2141.

Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, Longhi R, Colombo MP, Dougan G, Rescigno M (2005) Cancer immunotherapy based on killing of *Salmonella*-infected tumor cells. *Cancer Res* **65**: 3920–3927.

Bajaj V, Hwang C, Lee CA (1995) hilA is a novel ompR/toxR family member that activates the expression of *Salmonella typhimurium* invasion genes. *Mol Microbiol* **18**: 715–727.

Baumler AJ, Tsolis RM, Ficht TA, Adams LG (1998) Evolution of host adaptation in *Salmonella enterica*. *Infect Immun* **66**: 4579–4587.

Bereta M, Hayhurst A, Gajda M, Chorobik P, Targosz M, Marcinkiewicz J, Kaufman HL (2007) Improving tumor targeting and therapeutic potential of *Salmonella* VNP20009 by displaying cell surface CEA-specific antibodies. *Vaccine* **25**: 4183–4192.

Bermudes D, Zheng LM, King IC (2002) Live bacteria as anticancer agents and tumor-selective protein delivery vectors. *Curr Opin Drug Discov Devel* **5**: 194–199.

Blache CA, Manuel ER, Kaltcheva TI, Wong AN, Ellenhorn JD, Blazar BR, Diamond DJ (2012) Systemic delivery of *Salmonella typhimurium* transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. *Cancer Res* **72**: 6447–6456.

Cao HD, Yang YX, Lu L, Liu SN, Wang PL, Tao XH, Wang LJ, Xi-ang TX (2010) Attenuated *Salmonella typhimurium* carrying TRAIL and VP3 genes inhibits the growth of gastric cancer cells *in vitro* and *in vivo*. *Tumori* **96**: 296–303.

Chakravorty D, Hansen-Wester I, Hensel M (2002) *Salmonella* pathogenicity island 2 mediates protection of intracellular *Salmonella* from reactive nitrogen intermediates. *J Exp Med* **195**: 1155–1166.

Chatfield SN, Charles IG, Makoff AJ, Oxer MD, Dougan G, Pickard D, Slater D, Fairweather NF (1992) Use of the nirB promoter to direct the stable expression of heterologous antigens in *Salmonella* oral vaccine strains: development of a single-dose oral tetanus vaccine. *Biotechnology (NY)* **10**: 888–892.

Chen J, Yang B, Cheng X, Qiao Y, Tang B, Chen G, Wei J, Liu X, Cheng W, Du P, Huang X, Jiang W, Hu Q, Hu Y, Li J, Hua ZC (2012) *Salmonella*-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model. *Cancer Sci* **103**: 325–333.

Chorobik P, Marcinkiewicz M (2011) Therapeutic vaccines based on genetically modified *Salmonella*: a novel strategy in cancer immunotherapy. *Polskie Archiwum Medycyny Wewnętrznej* **121**: 461–466.

Chou CK, Hung JY, Liu JC, Chen CT, Hung MC (2006) An attenuated *Salmonella* oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein. *Cancer Gene Ther* **13**: 746–752.

Dai MS, Nitchau-Tefit J, Alcock S, Ramirez-Jimenez F, Chao TY, Baril P, Rocha M, Brett SJ, Stauss HJ, Vassaux G (2009) Development of an *Escherichia coli* expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors. *J Immunother* **32**: 845–855.

Dang LH, Bettgeowda C, Huso DL, Kinzler KW, Vogelstein B (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. *Proc Natl Acad Sci USA* **98**: 15155–15160.

Deng Y, Lin Y, Wu X (2002) TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. *Genes Dev* **16**: 33–45.

Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA (2012) Invasive non-typhoidal *Salmonella* disease: an emerging and neglected tropical disease in Africa. *Lancet* **379**: 2489–2499.

Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, Baykan B, Zenclussen AC, Michalsky E, Jaeger IS, Preissner R, Hohn O, Weixler S, Gaedicke G, Lode HN (2009) Survivin mini-gene DNA vaccination is effective against neuroblastoma. *Int J Cancer* **125**: 104–114.

Forbes NS (2010) Engineering the perfect (bacterial) cancer therapy. *Nat Rev Cancer* **10**: 785–794.

Fu W, Chu L, Han X, Liu X, Ren D (2008) Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated *Salmonella enterica* Serovar *Typhimurium* in murine tumor models. *J Gene Med* **10**: 690–701.

Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma *in vivo*. *Nat Med* **8**: 808–815.

Galan JE, Collmer A (1999) Type III secretion machines: bacterial devices for protein delivery into host cells. *Science* **284**: 1322–1328.

Galmbacher K, Heisig M, Hotz C, Wischhusen J, Galmiche A, Bergmann B, Gentschev I, Goebel W, Rapp UR, Fensterle J (2010) *Shigella* mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. *PLoS One* **5**: e9572.

Ganai S, Arenas RB, Forbes NS (2009) Tumor-targeted delivery of TRAIL using *Salmonella typhimurium* enhances breast cancer survival in mice. *Br J Cancer* **101**: 1683–1691.

Garmory HS, Brown KA, Titball RW (2002) *Salmonella* vaccines for use in humans: present and future perspectives. *FEMS Microbiol Rev* **26**: 339–353.

Green PN, Hopton Cann SA (2007) Bacterial anti-cancer vaccines: a science frozen in time. *Microbiologist* **8**: 29–34.

Guibourdenche M, Roggentin P, Mikoleit M, Fields PI, Bockemuhl J, Grimont PA, Weill FX (2010) Supplement 2003–2007 (No 47) to the White-Kauffmann-Le Minor scheme. *Res Microbiol* **161**: 26–29.

Guo CC, Ding J, Pan BR, Yu ZC, Han QL, Meng FP, Liu N, Fan DM (2003) Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated *Salmonella typhimurium* as carrier. *World J Gastroenterol* **9**: 1191–1195.

Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Hoffman RM (2009a) Cancer metastasis directly eradicated by targeted therapy with a modified *Salmonella typhimurium*. *J Cell Biochem* **106**: 992–998.

Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Kishimoto H, Bouvet M, Hoffman RM (2009b) Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of *Salmonella typhimurium*. *Cell Cycle* **8**: 870–875.

Heimann DM, Rosenberg SA (2003) Continuous intravenous administration of live genetically modified *Salmonella typhimurium* in patients with metastatic melanoma. *J Immunother* **26**: 179–180.

Hoiseith SK, Stocker BA (1985) Genes *aroA* and *serC* of *Salmonella typhimurium* constitute an operon. *J Bacteriol* **163**: 355–361.

Hong EH, Chang SY, Lee BR, Pyun AR, Kim JW, Kweon MN, Ko HJ (2013) Intratumoral injection of attenuated *Salmonella* vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. *Vaccine* **31**: 1377–1384.

Huebener N, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y, Gaedicke G, Lode HN (2008) A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. *Mol Cancer Ther* **7**: 2241–2251.

Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. *J Transl Med* **3**: 22.

Janssen R, van der Straaten T, van Diepen A, van Dissel JT (2003) Responses to reactive oxygen intermediates and virulence of *Salmonella typhimurium*. *Microbes Infect* **5**: 527–534.

Jarosz M, Jazowiecka-Rakus J, Cichon T, Glowala-Kosinska M, Smolarczyk R, Smagur A, Malina S, Sochanik A, Szala S (2013) Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. *Gene Ther* **20**: 262–273.

Jellbauer S, Panthel K, Hetrodt JH, Russmann H (2012) CD8 T-cell induction against vascular endothelial growth factor receptor 2 by *Salmonella* for vaccination purposes against a murine melanoma. *PLoS One* **7**: e34214.

Jepson MA, Clark MA (2001) The role of M cells in *Salmonella* infection. *Microbes Infect* **3**: 1183–1190.

Jesenberger V, Procyk KJ, Yuan J, Reipert S, Baccharini M (2000) *Salmonella*-induced caspase-2 activation in macrophages: a novel

- mechanism in pathogen-mediated apoptosis. *J Exp Med* **192**: 1035–1046.
- Karbach J, Neumann A, Brand K, Wahle C, Siegel E, Maeurer M, Ritter E, Tsuji T, Gnjatic S, Old LJ, Ritter G, Jager E (2012) Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. *Clin Cancer Res* **18**: 5449–5459.
- Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H (2013) *Bacillus Calmette-Guerin* (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. *Cancer Sci* **104**: 22–27.
- Kim JM, Eckmann L, Savidge TC, Lowe DC, Witthoft T, Kagnoff MF (1998) Apoptosis of human intestinal epithelial cells after bacterial invasion. *J Clin Invest* **102**: 1815–1823.
- Kimura H, Zhang L, Zhao M, Hayashi K, Tsuchiya H, Tomita K, Bouvet M, Wessels J, Hoffman RM (2010) Targeted therapy of spinal cord glioma with a genetically modified *Salmonella typhimurium*. *Cell Prolif* **43**: 41–48.
- Knodler LA, Vallance BA, Celli J, Winfree S, Hansen B, Montero M, Steele-Mortimer O (2010) Dissemination of invasive *Salmonella* via bacterial-induced extrusion of mucosal epithelia. *Proc Natl Acad Sci USA* **107**: 17733–17738.
- Kolyva S, Waxin H, Popoff MY (1992) The Vi antigen of *Salmonella typhi*: molecular analysis of the viaB locus. *J Gen Microbiol* **138**: 297–304.
- LeBlanc HN, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. *Cell Death Differ* **10**: 66–75.
- Lee KC, Zheng L-M, Luo X, Clairmont C, Fischer J, Margitich D, Turnier J, Almassian B, Bermudes D, King I (2000) Comparative evaluation of the acute toxic effects in monkeys, pigs and mice of a genetically engineered *Salmonella* strain (VNP20009) being developed as an antitumor agent. *Int J Toxicol* **19**: 19–25.
- Loeffler M, Le'Negrate G, Krajewska M, Reed JC (2008) IL-18-producing *Salmonella* inhibit tumor growth. *Cancer Gene Ther* **15**: 787–794.
- Loeffler M, Le'Negrate G, Krajewska M, Reed JC (2009) *Salmonella typhimurium* engineered to produce CCL21 inhibit tumor growth. *Cancer Immunol Immunother* **58**: 769–775.
- Low KB, Ittensohn M, Luo X, Zheng LM, King I, Pawelek JM, Bermudes D (2004) Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting *Salmonella* for parenteral administration in humans. *Methods Mol Med* **90**: 47–60.
- Lucas RL, Lostro CP, DiRusso CC, Spector MP, Wanner BL, Lee CA (2000) Multiple factors independently regulate hilA and invasion gene expression in *Salmonella enterica* serovar *typhimurium*. *J Bacteriol* **182**: 1872–1882.
- Malik-Kale P, Jolly CE, Lathrop S, Winfree S, Luterbach C, Steele-Mortimer O (2011) *Salmonella* — at home in the host cell. *Front Microbiol* **2**: 125.
- Malik-Kale P, Winfree S, Steele-Mortimer O (2012) The bimodal life-style of intracellular *Salmonella* in epithelial cells: replication in the cytosol obscures defects in vacuolar replication. *PLoS One* **7**: e38732.
- Manuel ER, Blache CA, Paquette R, Kalcheva TI, Ishizaki H, Ellenhorn JD, Hensel M, Metelitsa L, Diamond DJ (2011) Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting *Salmonella*-based STAT3 shRNA suppresses the growth of established melanoma tumors. *Cancer Res* **71**: 4183–4191.
- Martinez-Argudo I, Jepson MA (2008) *Salmonella* translocates across an in vitro M cell model independently of SPI-1 and SPI-2. *Microbiology* **154**: 3887–3894.
- McCarthy EF (2006) The toxins of William B Coley and the treatment of bone and soft-tissue sarcomas. *Iowa Orthop J* **26**: 154–148.
- McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK (2001) Complete genome sequence of *Salmonella enterica* serovar *Typhimurium* LT2. *Nature* **413**: 852–856.
- Meng FP, Ding J, Yu ZC, Han QL, Guo CC, Liu N, Fan DM (2005) Oral attenuated *Salmonella typhimurium* vaccine against MG7-Ag mouse model of gastric cancer. *World J Gastroenterol* **11**: 1833–1836.
- Meng JZ, Dong YJ, Huang H, Li S, Zhong Y, Liu SL, Wang YD (2010) Oral vaccination with attenuated *Salmonella enterica* strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses. *Clin Vaccine Immunol* **17**: 89–94.
- Monack DM, Raupach B, Hromockyj AE, Falkow S (1996) *Salmonella typhimurium* invasion induces apoptosis in infected macrophages. *Proc Natl Acad Sci USA* **93**: 9833–9838.
- Nagakura C, Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM (2009) Efficacy of a genetically modified *Salmonella typhimurium* in an orthotopic human pancreatic cancer in nude mice. *Anticancer Res* **29**: 1873–1878.
- Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, Grenacher L, Buchler MW, Koch M, Weitz J, Haefeli WE, Schmitz-Winenthal FH (2012) Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. *BMC Cancer* **12**: 361.
- Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y, Ritter G, Jager E, Nomura H, Kondo S, Tawara I, Kato T, Shiku H, Old LJ, Galan JE, Gnjatic S (2006) *In vivo* antigen delivery by a *Salmonella typhimurium* type III secretion system for therapeutic cancer vaccines. *J Clin Invest* **116**: 1946–1954.
- Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP (1998) Gene transfer in dendritic cells, induced by oral DNA vaccination with *Salmonella typhimurium*, results in protective immunity against a murine fibrosarcoma. *Blood* **92**: 3172–3176.
- Pantel K, Meinel KM, Domenech VE, Retzbach H, Igwe EI, Hardt WD, Russmann H (2005) *Salmonella* pathogenicity island 2-mediated overexpression of chimeric SspH2 proteins for simultaneous induction of antigen-specific CD4 and CD8 T cells. *Infect Immun* **73**: 334–341.
- Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ (2002) Typhoid fever. *N Engl J Med* **347**: 1770–1782.
- Paterson Y, Guirnalda PD, Wood LM (2010) *Listeria* and *Salmonella* bacterial vectors of tumor-associated antigens for cancer immunotherapy. *Semin Immunol* **22**: 183–189.
- Pawelek JM, Low KB, Bermudes D (1997) Tumor-targeted *Salmonella* as a novel anticancer vector. *Cancer Res* **57**: 4537–4544.
- Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C, Liu X (2004) An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. *Hepatolgy* **39**: 1371–1381.
- Raupach B, Kaufmann S H (2001) Bacterial virulence, proinflammatory cytokines and host immunity: how to choose the appropriate *Salmonella* vaccine strain? *Microbes Infect* **3**: 1261–1269.
- Raupach B, Kurth N, Pfeffer K, Kaufmann SH (2003) *Salmonella typhimurium* strains carrying independent mutations display similar virulence phenotypes yet are controlled by distinct host defense mechanisms. *J Immunol* **170**: 6133–6140.
- Richardson MA, Ramirez T, Russell NC, Moye LA (1999) Coley toxins immunotherapy: a retrospective review. *Altern Ther Health Med* **5**: 42–47.
- Saltzman DA, Heise CP, Hasz DE, Zebede M, Kelly SM, Curtiss R 3rd, Leonard AS, Anderson PM (1996) Attenuated *Salmonella typhimurium* containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. *Cancer Biother Radiopharm* **11**: 145–153.
- Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggett G, Minchin RF, Guminski A (2012) Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. *EMBO Mol Med* **4**: 675–684.
- Schroeder N, Mota LJ, Meresse S (2011) *Salmonella*-induced tubular networks. *Trends Microbiol* **19**: 268–277.
- Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. *J Natl Cancer Inst* **100**: 649–662.
- Shwartzman G (1928) Studies on *Bacillus typhosus* toxic substances: I phenomenon of local skin reactivity to B typhosus culture filtrate. *J Exp Med* **48**: 247–68.
- Shwartzman G (1935) Hemorrhagic necrosis and regression sarcoma 180. *Science* **82**: 201.
- Singh R, Wallecha A (2011) Cancer immunotherapy using recombinant *Listeria monocytogenes*: transition from bench to clinic. *Hum Vaccin* **7**: 497–505.
- Song J, Willinger T, Rongvaux A, Eynon EE, Stevens S, Manz MG, Flavell RA, Galan JE (2010) A mouse model for the human pathogen *Salmonella typhi*. *Cell Host Microbe* **8**: 369–376.
- St Jean AT, Zhang M, Forbes NS (2008) Bacterial therapies: completing the cancer treatment toolbox. *Curr Opin Biotechnol* **19**: 511–517.
- Steele-Mortimer O (2008) The *Salmonella*-containing vacuole: moving with the times. *Curr Opin Microbiol* **11**: 38–45.
- Steele-Mortimer O, Meresse S, Gorvel JP, Toh BH, Finlay BB (1999) Biogenesis of *Salmonella typhimurium*-containing vacuoles in epithelial cells involves interactions with the early endocytic pathway. *Cell Microbiol* **1**: 33–49.
- Stritzker J, Weibel S, Seubert C, Gotz A, Tresch A, van Rooijen N, Oelschlaeger TA, Hill PJ, Gentschev I, Szalay AA (2010) Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of chemotaxis and motility. *Int J Med Microbiol* **300**: 449–56.
- Strugnell R, Dougan G, Chatfield S, Charles I, Fairweather N, Tite J, Li JL, Beesley J, Roberts M (1992) Characterization of a *Salmonella typhimurium* aro vaccine strain expressing the P 69 antigen of *Bordetella pertussis*. *Infect Immun* **60**: 3994–4002.
- Swart AL, Hensel M (2012) Interactions of *Salmonella enterica* with dendritic cells. *Virulence* **3** (Epub ahead of print).
- Tangney M, van Pijkeren JP, Gahan CG (2010) The use of *Listeria monocytogenes* as a DNA delivery vector for cancer gene therapy. *Bioeng Bugs* **1**: 284–287.

- Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG (2005) Systemic administration of an attenuated, tumor-targeting *Salmonella typhimurium* to dogs with spontaneous neoplasia: phase I evaluation. *Clin Cancer Res* **11**: 4827–4834.
- Tindall BJ, Grimont PA, Garrity GM, Euzéby JP (2005) Nomenclature and taxonomy of the genus *Salmonella*. *Int J Syst Evol Microbiol* **55**: 521–524.
- Toley BJ, Forbes NS (2012) Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. *Integr Biol (Camb)* **4**: 165–176.
- Tome Y, Zhang Y, Momiyama M, Machara H, Kanaya F, Tomita K, Tsuchiya H, Bouvet M, Hoffman RM, Zhao M (2013) Primer dosing of *S. typhimurium* A1-R potentiates tumor-targeting and efficacy in immunocompetent mice. *Anticancer Res* **33**: 97–102.
- Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer IJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA (2002) Phase I study of the intravenous administration of attenuated *Salmonella typhimurium* to patients with metastatic melanoma. *J Clin Oncol* **20**: 142–152.
- Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, Kerbel RS (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. *Biochem Biophys Res Commun* **264**: 781–788.
- Umer B, Good D, Anne J, Duan W, Wei MQ (2012) Clostridial spores for cancer therapy: targeting solid tumour microenvironment. *J Toxicol* **2012**: 862764.
- Velge P, Wiedemann A, Rosselin M, Abed N, Boumart Z, Chausse AM, Grepinet O, Namdari F, Roche SM, Rossignol A, Virlogeux-Payant I (2012) Multiplicity of *Salmonella* entry mechanisms, a new paradigm for *Salmonella* pathogenesis. *Microbiologyopen* **1**: 243–258.
- Vendrell A, Gravisaco MJ, Pasetti MF, Croci M, Colombo L, Rodriguez C, Mongini C, Waldner CI (2011) A novel *Salmonella* Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. *Vaccine* **29**: 728–736.
- Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumorcidal activity of tumor necrosis factor-related apoptosis-inducing ligand *in vivo*. *Nat Med* **5**: 157–163.
- Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN, Dolman CS, Gillies SD, Reisfeld RA (2001) A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. *J Immunol* **167**: 4560–4565.
- Xiong G, Husseiny MI, Song L, Erdreich-Epstein A, Shackleford GM, Seeger RC, Jackel D, Hensel M, Metelitsa LS (2010) Novel cancer vaccine based on genes of *Salmonella* pathogenicity island 2. *Int J Cancer* **126**: 2622–2634.
- Yagita H, Takeda K, Hayakawa Y, Smyth M J, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. *Cancer Sci* **95**: 777–783.
- Yoon WS, Chae YS, Hong J, Park YK (2011) Antitumor therapeutic effects of a genetically engineered *Salmonella typhimurium* harboring TNF-alpha in mice. *Appl Microbiol Biotechnol* **89**: 1807–1819.
- Yrliid U, Wick MJ (2000) *Salmonella*-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. *J Exp Med* **191**: 613–624.
- Yu B, Yang M, Shi L, Yao Y, Jiang Q, Li X, Tang LH, Zheng B J, Yuen KY, Smith DK, Song E, Huang JD (2012) Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic *Salmonella* Typhimurium strain. *Sci Rep* **2**: 436.
- Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P (2001) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. *Cancer Res* **61**: 7339–7348.
- Zhang Y, Tome Y, Suetsugu A, Zhang L, Zhang N, Hoffman RM, Zhao M (2012a) Determination of the optimal route of administration of *Salmonella typhimurium* A1-R to target breast cancer in nude mice. *Anticancer Res* **32**: 501–508.
- Zhang Y, Xia L, Zhang X, Ding X, Yan F, Wu F (2012b) *Escherichia coli* Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. *Appl Environ Microbiol* **78**: 7603–7610.
- Zhao M, Geller J, Ma H, Yang M, Penman S, Hoffman RM (2007) Monotherapy with a tumor-targeting mutant of *Salmonella typhimurium* cures orthotopic metastatic mouse models of human prostate cancer. *Proc Natl Acad Sci USA* **104**: 10170–10174.
- Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing *Salmonella typhimurium*. *Proc Natl Acad Sci USA* **102**: 755–760.
- Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z, Hoffman RM (2006) Targeted therapy with a *Salmonella typhimurium* leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. *Cancer Res* **66**: 7647–7652.
- Zhu X, Zhou P, Cai J, Yang G, Liang S, Ren D (2010) Tumor antigen delivered by *Salmonella* III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma. *Cancer Sci* **101**: 2621–2628.
- Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb AJ, Noteborn MH (1995) Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. *Cancer Res* **55**: 486–489.